Tutors International Releases Study on Merging Classical and Contemporary Teaching Techniques
OXFORD, England, March 25, 2025 /PRNewswire/ -- Tutors International, a leading provider of bespoke private tutoring services, has released a comprehensive analysis examining the integration of ancient educational philosophies with contemporary teaching practices.
The analysis highlights how blending time-honored methods with modern innovations can enhance learning experiences for students today.
Adam Caller, Founder of Tutors International, commented:
"The most effective education isn't about choosing between traditional or modern approaches - it's about weaving them together to create deeper, more personalised learning experiences."
The historical foundations of today's educational methods
The analysis traces the evolution of educational techniques from ancient civilizations to the present, identifying enduring practices such as:
Socratic Method: Originating in ancient Greece, this approach fosters critical thinking through guided questioning, paralleling today's inquiry-based learning strategies.
Apprenticeship Model: Historically involving direct mentorship and hands-on experience, this model has evolved into competency-based education, emphasizing skill mastery and practical application.
Gurukul System: From ancient India, this holistic, residential form of education emphasised personalised mentorship, akin to modern one-on-one tutoring and homeschooling practices.
Contemporary pedagogical approaches
The report also examines contemporary pedagogical approaches that have gained prominence, including:
Blended Learning: Combining online resources with traditional classroom instruction, this method has become increasingly prevalent, especially following the acceleration of digital adoption during the COVID-19 pandemic.
Project-Based Learning (PBL): Engaging students in complex, real-world projects to develop problem-solving skills, PBL is widely adopted in STEM fields, business programs, and design disciplines.
Culturally Responsive Teaching (CRT): Addressing diversity and inclusion, CRT emphasises adapting instruction to the cultural contexts of students, fostering more effective and inclusive learning environments.
Tutors International advocates for a balanced integration of ancient and modern educational strategies to create optimal learning experiences. For instance:
- Combining the Socratic Method with constructivist learning theories can enhance critical thinking.
- The personalised mentorship inherent in the Gurukul system aligns with fostering a growth mindset in students.
The analysis underscores the unique position of private tutors in implementing this blended approach. By tailoring instruction to individual learning styles and needs, private tutors can seamlessly incorporate both traditional wisdom and modern techniques, facilitating holistic development and academic excellence.
About Tutors International
Tutors International provides unparalleled private tutoring services, offering full-time residential positions, travel tutors, and home-schooling education solutions to clients worldwide, and specialises in finding the perfect tutor to match each student's specific needs. Founded by Adam Caller, an expert in educational practice and private tutoring, Tutors International's select clientele receives a personally tailored service, with discretion and confidentiality guaranteed.
Media enquiries Web: www.tutors-international.comEmail: marketing@tutors-international.com Phone: +44 (0) 1865 435 135
Tutors InternationalPrama House267 Banbury RoadOxford OX2 7HTEngland
Logo - https://mma.prnewswire.com/media/699064/5234126/Tutors_International_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/tutors-international-releases-study-on-merging-classical-and-contemporary-teaching-techniques-302410932.html
SOURCE Tutors International
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
28 minutes ago
- Bloomberg
BioNTech to Buy CureVac for $1.25 Billion to Boost Cancer Arm
BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business. CureVac investors will get approximately $5.46 in BioNTech shares for each CureVac one, the companies said Thursday. The price represents a 34% premium to CureVac's closing share price on Wednesday. CureVac shareholders will own between 4% and 6% of BioNTech once the deal closes.
Yahoo
31 minutes ago
- Yahoo
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% DZD8586 exhibited significant antitumor activity in heavily pretreated chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients with an objective response rate (ORR) of 84.2% Both golidocitinib and DZD8586 will be featured in oral presentations at ICML 2025, with DZD8586 also presented in an oral session at ASCO 2025 SHANGHAI, June 12, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that it will present research findings on two of its first-in-class hematologic oncology assets—golidocitinib and DZD8586—at the 2025 European Hematology Association (EHA) Annual Congress and the 18th International Conference on Malignant Lymphoma (ICML). These include long-term follow-up data on golidocitinib as a maintenance therapy in peripheral T-cell lymphoma (PTCL) after first-line systemic therapy and pooled analysis results for DZD8586 in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), both selected for oral presentations at ICML. Golidocitinib Shows Potential to Significantly Improve Patient Outcomes in PTCL PTCL patients who achieved tumor response with first-line standard therapy will relapse. Approximately 40% of patients with complete response and 80% with partial response experienced disease progression within 2 years after initial tumor response, and the prognosis of these relapsed patients was very poor. The 24-month follow-up results from JACKPOT26, a prospective, multicenter Phase 2 clinical study of golidocitinib will be unveiled at EHA and featured as an oral presentation at ICML. The data suggest that golidocitinib showed promising efficacy in maintaining and enhancing tumor response with an acceptable and manageable safety profile in patients with PTCLs post first-line therapies. In Cohort 1 (patients with complete response), the 24-month disease-free survival (DFS) rate reached 74.2%, with consistent efficacy observed across different subtypes. In Cohort 2 (patients with partial response), the complete response rate (CRR) was 50.0%, the median duration of response (DoR) was 23.9 months, and the median progression-free survival (PFS) was 17.4 months, with the longest PFS reaching 35.9 months and the patient was still responding. "Golidocitinib, a next-generation oral and highly selective JAK1 inhibitor, addresses a critical unmet need for effective maintenance therapy following first-line treatment in PTCL," said Professor Jie Jin, lead principal investigator of the JACKPOT26 study at the First Affiliated Hospital of Zhejiang University School of Medicine. "Its unique mechanism of action not only delivers strong anti-tumor activity—allowing 50% of patients with partial remission (PR) to achieve complete remission (CR)—but also modulates the tumor immune microenvironment through its anti-inflammatory and immunomodulatory effects. These unique features help delay relapse and extend survival, positioning golidocitinib as a highly promising option for maintenance therapy in PTCL." In addition, golidocitinib has shown encouraging antitumor activities and favorable safety profiles in combination with CHOP in 1st line PTCL patients, as well as in rare T-cell lymphoma subtypes, including relapsed/refractory T-cell large granular lymphocytic leukemia (r/r T-LGLL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). Further studies are warranted to validate the results. DZD8586 Overcomes Multi-Drug Resistance in CLL and other B-NHL A pooled analysis of two phase I/II studies of DZD8586 in CLL/SLL patients previously treated with covalent/non-covalent Bruton's Tyrosine Kinase (BTK) inhibitors and BTK degraders was presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and will be presented at EHA. Subgroup analyses will be presented as an oral presentation at ICML. In heavily pretreated CLL/SLL, DZD8586 achieved an ORR of 84.2%. Tumor response with a manageable safety profile was observed irrespective of prior covalent/non-covalent BTKi, BTK degrader, or BCL-2 inhibitor treatment, and in patients with classic BTK resistance mutations (C481X) as well as other BTK mutations, including kinase-dead mutations. No drug-related bleeding, atrial fibrillation, or major cardiac events observed. A Phase II study of DZD8586 monotherapy in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) will also be presented at EHA and ICML. Clinical activities from small molecule targeted drugs such as BTK inhibitors have been less than desired for the treatment of DLBCL. Compensatory or redundant pathway activation could be one of the main escape mechanisms. DZD8586, a novel LYN/BTK dual inhibitor, is designed to overcome these limitations by blocking both BTK and LYN signaling pathways, and thus potentially improve therapeutic outcomes. At recommended phase 2 doses (RP2Ds) of 50 mg and 75 mg QD, DZD8586 monotherapy demonstrated promising anti-tumor activity in r/r DLBCL. The majority of patients showed target lesion shrinkage, with a CRR of 35.5%. Complete responders showed durable responses, with 81.8% of patients remaining in response and the median DoR was not reached. Notably, it showed efficacy in both GCB and non-GCB subtypes, supporting its broad therapeutic potential. Dr. Xiaolin Zhang, CEO of Dizal, remarked, "We are excited that golidocitinib and DZD8586 have demonstrated promising potential in PTCL and B-cell non-Hodgkin lymphoma (B-NHL), two areas with substantial unmet clinical needs. The selection of multiple studies for oral presentations at global leading conferences represents a strong recognition of our capabilities in research and development and further affirms our commitment to bringing transformative therapies to patients worldwide." About golidocitinib (DZD4205)Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months. Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4). About DZD8586DZD8586 is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL). While Bruton's Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect long-term clinical application. DZD8586 has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. Phase I clinical trial suggests that DZD8586 exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL. About DizalDizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deeply rooted in translational science and molecular design, it has established an internationally competitive portfolio with two leading assets in global pivotal studies, both of which have already been launched in China. To learn more about Dizal, please visit or follow us on Linkedin or X. Forward-Looking StatementsThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions. Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect. ContactsInvestor Relations: ir@ Development: bd@ Contact: pr@ View original content to download multimedia: SOURCE Dizal Pharmaceutical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Etsy Announces Pricing of $650 Million of Convertible Senior Notes Offering
BROOKLYN, N.Y., June 12, 2025 /PRNewswire/ -- Etsy, Inc. (Nasdaq: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced the pricing of $650 million aggregate principal amount of 1.00% convertible senior notes due 2030 (the "notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Etsy also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $50 million aggregate principal amount of notes. The sale of the notes is expected to close on June 16, 2025, subject to customary closing conditions. The notes will be general unsecured obligations of Etsy and will accrue interest payable semiannually in arrears on June 15 and December 15 of each year, beginning on December 15, 2025, at a rate of 1.00% per year. The notes will mature on June 15, 2030, unless earlier converted, redeemed or repurchased. The initial conversion rate will be 11.6570 shares of Etsy's common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $85.79 per share). The initial conversion price of the notes represents a premium of approximately 42.5% over the last reported sale price of Etsy's common stock on June 11, 2025. The notes will be convertible into cash, shares of Etsy's common stock or a combination of cash and shares of Etsy's common stock, at Etsy's election. Etsy may redeem for cash all or (subject to certain limitations) any portion of the notes, at its option, on or after June 20, 2028 if the last reported sale price of Etsy's common stock has been at least 130% of the conversion price of the notes then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which Etsy provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Etsy provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If Etsy undergoes a "Fundamental Change" (as defined in the indenture governing the notes), subject to certain conditions and limited exceptions, holders of the notes may require Etsy to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date of the notes or if Etsy delivers a notice of redemption in respect of the notes, Etsy will, in certain circumstances, increase the conversion rate of the notes for a holder who elects to convert its notes in connection with such a corporate event or convert its notes called (or deemed called) for redemption in connection with such notice of redemption, as the case may be. Etsy estimates that the net proceeds from the offering will be approximately $639.3 million (or approximately $688.5 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers' discount and estimated offering expenses payable by Etsy. Etsy expects to use approximately $150.0 million of the net proceeds from the offering to repurchase shares of Etsy's common stock as described below, and the remainder of the net proceeds from the offering for general corporate purposes, which may include the repayment or repurchase, at or prior to maturity, of our existing debt securities. Neither the notes nor any shares of Etsy's common stock issuable upon conversion of the notes have been registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. Concurrently with the pricing of the offering, Etsy entered into privately negotiated transactions effected with or through one of the initial purchasers or its affiliates to use approximately $150.0 million of the net proceeds from the offering to repurchase shares of Etsy's common stock at a repurchase price per share equal to $60.20 (the last reported sale price per share of Etsy's common stock on June 11, 2025). In addition, following the offering Etsy may repurchase additional shares of Etsy's common stock pursuant to its existing stock repurchase program. These repurchases could increase (or reduce the size of any decrease in) the market price of Etsy's common stock or the notes. In the case of repurchases effected concurrently with the offering, this activity could have affected the market price of Etsy's common stock prior to, concurrently with or shortly after the pricing of the notes, and could have resulted in a higher effective conversion price for the notes. This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Etsy Etsy, Inc. operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world. These marketplaces share a mission to "Keep Commerce Human," and we're committed to using the power of business and technology to strengthen communities and empower people. Our primary marketplace, is the global destination for unique and creative goods. Buyers come to Etsy to be inspired and delighted by items that are crafted and curated by creative entrepreneurs. For sellers, we offer a range of tools and services that address key business needs. Etsy, Inc. also owns fashion resale marketplace Depop. Etsy's marketplaces operate independently, while benefiting from shared expertise in product, marketing, technology, and customer support. Etsy was founded in 2005 and is headquartered in Brooklyn, New York. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, but are not limited to, statements concerning the expected closing of the offering and the share repurchases, the anticipated use of proceeds from the offering, the timing or amount of any repurchases of common stock by Etsy and the potential impact of the foregoing or related transactions on dilution to holders of Etsy's common stock or the market price of Etsy's common stock or the notes. Forward-looking statements include all statements that are not historical facts. In some cases, forward-looking statements can be identified by terms such as "anticipates," "believes," "could," "enables," "estimates," "expects," "intends," "may," "plans," "potential," "will," or similar expressions and derivative forms and/or the negatives of those words. Forward-looking statements involve substantial risks and uncertainties that may cause actual results to differ materially from those that Etsy expects. These risks and uncertainties include market risks, trends and conditions. These risks and uncertainties are more fully described in Etsy's filings with the Securities and Exchange Commission, including in the section titled "Risk Factors" in Etsy's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and subsequent reports that Etsy files with the Securities and Exchange Commission. In light of these risks, you should not place undue reliance on such forward-looking statements. Forward-looking statements represent Etsy's beliefs and assumptions only as of the date of this press release. Etsy disclaims any obligation to update forward-looking statements. Investor Relations Contact: Deb Wasser, Vice President, Investor Relationsir@ or Sarah Marx, Senior Director, Investor Relationsir@ Media Relations Contact:Lauren Bayse, Senior Director, Corporate Communicationspress@ View original content: SOURCE Etsy, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
